JP2015512433A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015512433A5 JP2015512433A5 JP2015503848A JP2015503848A JP2015512433A5 JP 2015512433 A5 JP2015512433 A5 JP 2015512433A5 JP 2015503848 A JP2015503848 A JP 2015503848A JP 2015503848 A JP2015503848 A JP 2015503848A JP 2015512433 A5 JP2015512433 A5 JP 2015512433A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- weight
- disintegrant
- diluent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12163078 | 2012-04-04 | ||
| EP12163078.4 | 2012-04-04 | ||
| PCT/EP2013/056867 WO2013149987A1 (en) | 2012-04-04 | 2013-04-02 | Pharmaceutical formulations comprising ccr3 antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018072309A Division JP6700332B2 (ja) | 2012-04-04 | 2018-04-04 | Ｃｃｒ３アンタゴニストを含む医薬製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015512433A JP2015512433A (ja) | 2015-04-27 |
| JP2015512433A5 true JP2015512433A5 (cg-RX-API-DMAC7.html) | 2016-06-02 |
| JP6320990B2 JP6320990B2 (ja) | 2018-05-09 |
Family
ID=49292482
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503848A Active JP6320990B2 (ja) | 2012-04-04 | 2013-04-02 | Ｃｃｒ３アンタゴニストを含む医薬製剤 |
| JP2018072309A Active JP6700332B2 (ja) | 2012-04-04 | 2018-04-04 | Ｃｃｒ３アンタゴニストを含む医薬製剤 |
| JP2020080024A Pending JP2020143080A (ja) | 2012-04-04 | 2020-04-30 | Ｃｃｒ３アンタゴニストを含む医薬製剤 |
| JP2022026735A Pending JP2022081524A (ja) | 2012-04-04 | 2022-02-24 | Ｃｃｒ３アンタゴニストを含む医薬製剤 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018072309A Active JP6700332B2 (ja) | 2012-04-04 | 2018-04-04 | Ｃｃｒ３アンタゴニストを含む医薬製剤 |
| JP2020080024A Pending JP2020143080A (ja) | 2012-04-04 | 2020-04-30 | Ｃｃｒ３アンタゴニストを含む医薬製剤 |
| JP2022026735A Pending JP2022081524A (ja) | 2012-04-04 | 2022-02-24 | Ｃｃｒ３アンタゴニストを含む医薬製剤 |
Country Status (31)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| UA109290C2 (uk) | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| AR090566A1 (es) | 2012-04-02 | 2014-11-19 | Boehringer Ingelheim Int | Proceso para la produccion de inhibidores de crr |
| US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) * | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| ES2950453T3 (es) | 2017-04-05 | 2023-10-10 | Alkahest Inc | Compuestos y composiciones farmacéuticas para su uso en el tratamiento de enfermedades asociadas a la retina utilizando inhibidores de la CCR3 |
| JP2020513005A (ja) * | 2017-04-05 | 2020-04-30 | アルカヘスト，インコーポレイテッド | Ｃｃｒ３阻害剤を用いて、加齢性機能障害を治療するための方法及び組成物 |
| JP2020536929A (ja) * | 2017-10-13 | 2020-12-17 | アルカヘスト，インコーポレイテッド | Ｃｃｒ３阻害剤を用いた、そう痒症、乾皮症、及び関連疾患を治療するための方法及び組成物 |
| SG11202010115RA (en) | 2018-05-15 | 2020-11-27 | Alkahest Inc | Treatment of aging-associated disease with modulators of leukotriene a4 hydrolase |
| EP3856195A4 (en) * | 2018-09-26 | 2022-06-22 | Alkahest, Inc. | METHODS AND COMPOSITIONS FOR TREATING DISORDERS RELATED TO AGING USING CCR3 INHIBITORS |
| EP4206153A4 (en) | 2020-08-27 | 2024-05-15 | Agc Inc. | ALKALI-FREE GLASS AND PLATE GLASS |
| JP2024542963A (ja) | 2021-11-01 | 2024-11-19 | アルカヘスト，インコーポレイテッド | 加齢関連疾患の予防及び治療のためのロイコトリエンａ４加水分解酵素（ｌｔａ４ｈ）のベンゾジオキサン調節剤 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7907121L (sv) | 1979-08-27 | 1981-02-28 | Astra Laekemedel Ab | Ftalimidinderivat |
| US4992277A (en) | 1989-08-25 | 1991-02-12 | Schering Corporation | Immediate release diltiazem formulation |
| JP2807577B2 (ja) | 1990-06-15 | 1998-10-08 | エーザイ株式会社 | 環状アミド誘導体 |
| IL116539A (en) * | 1995-01-06 | 2002-02-10 | Noven Pharma | Preparations given through the skin of unstable anti-acid drugs |
| AU7375598A (en) * | 1997-05-09 | 1998-11-27 | Sage Pharmaceuticals, Inc. | Stable oral pharmaceutical dosage forms |
| AU2335699A (en) | 1998-01-21 | 1999-08-09 | Kyowa Hakko Kogyo Co. Ltd. | Chemokine receptor antagonists and methods of use therefor |
| US6140349A (en) | 1998-02-02 | 2000-10-31 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| JP2002501898A (ja) | 1998-02-02 | 2002-01-22 | メルク エンド カムパニー インコーポレーテッド | ケモカイン受容体活性の環状アミン調節剤 |
| SE9802973D0 (sv) | 1998-09-03 | 1998-09-03 | Astra Ab | Immediate release tablet |
| EP2305257A1 (en) * | 2002-07-08 | 2011-04-06 | ChemGenex Pharmaceuticals, Inc. | Amonafide salts and compositions comprising same |
| CN1878793A (zh) | 2003-09-11 | 2006-12-13 | 鉴定医疗有限公司 | 拮抗hmgb1的单克隆抗体 |
| CN1871222A (zh) | 2003-10-24 | 2006-11-29 | 霍夫曼-拉罗奇有限公司 | Ccr3受体拮抗剂 |
| BRPI0416665A (pt) | 2003-11-17 | 2007-01-16 | Boehringer Ingelheim Int | indóis substituìdos com piperidina ou heteroderivados dos mesmos |
| WO2005077369A1 (en) | 2004-02-05 | 2005-08-25 | Schering Corporation | Piperidine derivatives useful as ccr3 antagonists |
| JP2006137718A (ja) | 2004-11-12 | 2006-06-01 | Astellas Pharma Inc | インドール若しくはインダゾール誘導体 |
| US8030003B2 (en) | 2004-12-07 | 2011-10-04 | Children's Hospital Medical Center | Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3 |
| DOP2006000051A (es) | 2005-02-24 | 2006-08-31 | Lilly Co Eli | Inhibidores de vegf-r2 y métodos |
| JP3701964B1 (ja) | 2005-03-08 | 2005-10-05 | アステラス製薬株式会社 | キヌクリジン誘導体の新規な塩 |
| CA2606550C (en) | 2005-04-30 | 2014-05-27 | Boehringer Ingelheim International Gmbh | Piperidine-substituted indoles |
| NL2000323C2 (nl) * | 2005-12-20 | 2007-11-20 | Pfizer Ltd | Pyrimidine-derivaten. |
| WO2007116313A2 (en) | 2006-04-12 | 2007-10-18 | Pfizer Limited | Pyrrolidine derivatives as modulators of chemokine ccr5 receptors |
| WO2008049874A1 (en) | 2006-10-27 | 2008-05-02 | Boehringer Ingelheim International Gmbh | Piperidyl-propane-thiol ccr3 modulators |
| CA2667548C (en) | 2006-10-27 | 2015-02-03 | Boehringer Ingelheim International Gmbh | Substituted piperidyl-propane-thiols |
| GB0701992D0 (en) | 2007-02-02 | 2007-03-14 | 7Tm Pharma As | Grehlin Receptor Modulators |
| US8008092B2 (en) | 2007-10-09 | 2011-08-30 | University Of Kentucky Research Foundation | CCR3 inhibition for ocular angiogenesis and macular degeneration |
| US8530488B2 (en) | 2007-10-24 | 2013-09-10 | Generics [Uk] Limited | Crystalline forms of bosentan |
| TW201000446A (en) | 2008-05-30 | 2010-01-01 | Astrazeneca Ab | New compounds useful in pain therapy |
| WO2010052727A1 (en) * | 2008-11-04 | 2010-05-14 | Ideal Cures Private Limited | High performance film coating compositions |
| US8278302B2 (en) * | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| CA2758968C (en) | 2009-04-22 | 2018-05-29 | Axikin Pharmaceuticals, Inc. | 2,5-disubstituted arylsulfonamide ccr3 antagonists |
| AR078120A1 (es) * | 2009-04-22 | 2011-10-19 | Axikin Pharmaceuticals Inc | Antagonistas de ccr3 de arilsulfonamida 2,5-disustituida y composiciones farmaceuticas |
| EP2523654A4 (en) * | 2010-01-11 | 2014-08-06 | Mohamed Shafee Muneera | IMMEDIATE RELEASE COMPOSITIONS OF MEDICAMENTS LABILES ACIDES |
| UA109290C2 (uk) | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| AR090566A1 (es) | 2012-04-02 | 2014-11-19 | Boehringer Ingelheim Int | Proceso para la produccion de inhibidores de crr |
| US20130261153A1 (en) | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) * | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
-
2013
- 2013-03-27 US US13/851,538 patent/US10213421B2/en active Active
- 2013-04-02 KR KR1020207021307A patent/KR102338465B1/ko active Active
- 2013-04-02 EP EP13714618.9A patent/EP2833864B1/en active Active
- 2013-04-02 BR BR112014024479A patent/BR112014024479A8/pt not_active Application Discontinuation
- 2013-04-02 PL PL13714618T patent/PL2833864T3/pl unknown
- 2013-04-02 AU AU2013245028A patent/AU2013245028B2/en active Active
- 2013-04-02 IN IN7082DEN2014 patent/IN2014DN07082A/en unknown
- 2013-04-02 NZ NZ628993A patent/NZ628993A/en unknown
- 2013-04-02 EA EA201401082A patent/EA027627B1/ru not_active IP Right Cessation
- 2013-04-02 JP JP2015503848A patent/JP6320990B2/ja active Active
- 2013-04-02 EP EP21190323.2A patent/EP3970693B1/en active Active
- 2013-04-02 WO PCT/EP2013/056867 patent/WO2013149987A1/en not_active Ceased
- 2013-04-02 HR HRP20190069TT patent/HRP20190069T1/hr unknown
- 2013-04-02 MX MX2014011787A patent/MX358307B/es active IP Right Grant
- 2013-04-02 LT LTEP13714618.9T patent/LT2833864T/lt unknown
- 2013-04-02 HU HUE13714618A patent/HUE041519T2/hu unknown
- 2013-04-02 CN CN201380016781.7A patent/CN104203213A/zh active Pending
- 2013-04-02 SI SI201331330T patent/SI2833864T1/sl unknown
- 2013-04-02 PL PL18213458T patent/PL3524230T3/pl unknown
- 2013-04-02 ES ES13714618T patent/ES2715844T3/es active Active
- 2013-04-02 RS RS20190050A patent/RS58360B1/sr unknown
- 2013-04-02 EP EP18213458.5A patent/EP3524230B1/en active Active
- 2013-04-02 DK DK13714618.9T patent/DK2833864T3/en active
- 2013-04-02 HU HUE18213458A patent/HUE056943T2/hu unknown
- 2013-04-02 KR KR1020147027802A patent/KR102138709B1/ko active Active
- 2013-04-02 ES ES21190323T patent/ES3044310T3/es active Active
- 2013-04-02 TR TR2018/21285T patent/TR201821285T4/tr unknown
- 2013-04-02 CA CA2869058A patent/CA2869058C/en active Active
- 2013-04-02 PT PT182134585T patent/PT3524230T/pt unknown
- 2013-04-02 SM SM20190121T patent/SMT201900121T1/it unknown
- 2013-04-02 DK DK18213458.5T patent/DK3524230T3/da active
- 2013-04-02 ES ES18213458T patent/ES2898179T3/es active Active
- 2013-04-02 PT PT13714618T patent/PT2833864T/pt unknown
- 2013-04-03 TW TW102112244A patent/TW201400115A/zh unknown
- 2013-04-03 AR ARP130101093A patent/AR090596A1/es unknown
- 2013-04-04 UY UY0001034730A patent/UY34730A/es unknown
-
2014
- 2014-08-26 IL IL234299A patent/IL234299A/en active IP Right Grant
- 2014-09-24 CL CL2014002524A patent/CL2014002524A1/es unknown
- 2014-10-03 PH PH12014502241A patent/PH12014502241A1/en unknown
-
2018
- 2018-04-04 JP JP2018072309A patent/JP6700332B2/ja active Active
- 2018-12-28 US US16/235,905 patent/US20190151300A1/en not_active Abandoned
-
2019
- 2019-01-17 CY CY20191100062T patent/CY1121137T1/el unknown
-
2020
- 2020-04-29 US US16/861,473 patent/US11612596B2/en active Active
- 2020-04-30 JP JP2020080024A patent/JP2020143080A/ja active Pending
-
2022
- 2022-02-24 JP JP2022026735A patent/JP2022081524A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015512433A5 (cg-RX-API-DMAC7.html) | ||
| JP6700332B2 (ja) | Ｃｃｒ３アンタゴニストを含む医薬製剤 | |
| JP2018021082A5 (cg-RX-API-DMAC7.html) | ||
| JP6487599B2 (ja) | エスシタロプラム医薬組成物 | |
| EA039006B1 (ru) | Ингибиторы тирозинкиназы | |
| TWI750143B (zh) | 含有2-{4-[n-(5,6-二苯基吡-2-基)-n-異丙基胺基]丁基氧基}-n-(甲基磺醯基)乙醯胺之醫藥組合物 | |
| US11331273B2 (en) | Film-coated tablet having high chemical stability of active ingredient | |
| KR101446129B1 (ko) | 프란루카스트-함유 고형 제제의 제조방법 | |
| JP2017031117A (ja) | 光安定性を向上した、イミダフェナシン製剤 | |
| WO2016079687A1 (en) | Oral pharmaceutical composition of teriflunomide | |
| JPWO2009123169A1 (ja) | アミド誘導体含有医薬組成物 | |
| EP1968593B1 (en) | Pharmaceutical composition comprising (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl-(3r,5s)-3,5-dihydroxyhept-6-enoic acid | |
| JP2016155777A (ja) | モンテルカスト又はその塩を含む組成物 | |
| WO2015069203A1 (en) | Capsule comprising rupatadine fumarate and montelukast sodium | |
| WO2011012987A1 (en) | Pharmaceutical composition of isoniazid | |
| JP6883401B2 (ja) | アジルサルタン含有錠剤及び錠剤におけるアジルサルタンの安定化方法 | |
| WO2020111089A1 (ja) | 医薬組成物 | |
| JP2020158435A (ja) | リナグリプチン含有医薬組成物及びその製造方法、並びにリナグリプチン含有医薬組成物の品質の向上方法 | |
| JP7271869B2 (ja) | レボセチリジン含有錠剤 | |
| JPWO2005030219A1 (ja) | ジアリールビニレン化合物の安定化方法 | |
| JP2014114243A (ja) | 安定な固形製剤の製造方法 | |
| WO2019132839A1 (en) | Oral pharmaceutical compositions of dabigatran | |
| JP2019073445A (ja) | アプレピタントを有効成分とする医薬組成物 | |
| JP6340270B2 (ja) | 安定なモンテルカストナトリウム含有経口固形医薬組成物、その製造方法、およびモンテルカストナトリウムの類縁物質生成抑制方法 | |
| JP6336651B1 (ja) | 化学的安定性が改善されたエソメプラゾール塩を含有する錠剤 |